House Dust Mite Allergy (Immunology) - Drugs in Development, 2021

March 2021 | 63 pages | ID: H4E1C58B2066EN
Global Markets Direct

Abstracts

House Dust Mite Allergy (Immunology) - Drugs in Development, 2021

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide House Dust Mite Allergy - Drugs in Development, 2021, provides an overview of the House Dust Mite Allergy (Immunology) pipeline landscape.

House dust mite allergy is an allergic reaction to tiny bugs that commonly live in house dust. Symptoms include frequent sneezing, a runny, stuffy, itchy nose and irritated eyes. Asthma and eczema can also be triggered by a dust mite allergy. Symptoms often worsen when the individual comes in close proximity to disturbed dust. The predisposing factors include family history and age. Treatment includes antihistamines, decongestants and corticosteroids.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide House Dust Mite Allergy - Drugs in Development, 2021, provides comprehensive information on the therapeutics under development for House Dust Mite Allergy (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The House Dust Mite Allergy (Immunology) pipeline guide also reviews of key players involved in therapeutic development for House Dust Mite Allergy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, Preclinical and Discovery stages are 2, 4, 3, 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

House Dust Mite Allergy (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of House Dust Mite Allergy (Immunology).
• The pipeline guide reviews pipeline therapeutics for House Dust Mite Allergy (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in House Dust Mite Allergy (Immunology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates House Dust Mite Allergy (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for House Dust Mite Allergy (Immunology)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for House Dust Mite Allergy (Immunology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding House Dust Mite Allergy (Immunology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
House Dust Mite Allergy - Overview
House Dust Mite Allergy - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
House Dust Mite Allergy - Therapeutics Assessment
Assessment by Target
Assessment by Route of Administration
Assessment by Molecule Type
House Dust Mite Allergy - Companies Involved in Therapeutics Development
Advagene Biopharma Co Ltd
ALK-Abello AS
Allergy Therapeutics Plc
Anergis SA
Astellas Pharma Inc
Biomay AG
Genetic Immunity Inc
Polyrizon Ltd
Roxall Medizin GmbH
Stallergenes Greer Ltd
Zhejiang I-Biological Technology Co Ltd
House Dust Mite Allergy - Drug Profiles
AD-17002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Allergen for Dust Mite Allergy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AM-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ASP-2390 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BM-35 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
clustoid d. pteronyssinus - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DermAll-HDM - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
house dust mite (Dermatophagoides farinae) allergen extract - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PL-103 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
standardized mite (Dermatophagoides farinae + Dermatophagoides pteronyssinus) allergen extract - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
standardized mite (Dermatophagoides pteronyssinus + Dermatophagoides farinae) allergen extract - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine for Grass Pollen Allergy and House Dust Mite Allergy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine for House Dust Mite Allergy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine for House Dust Mite Allergy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
House Dust Mite Allergy - Dormant Projects
House Dust Mite Allergy - Discontinued Products
House Dust Mite Allergy - Product Development Milestones
Featured News & Press Releases
May 04, 2020: Stallergenes Greer submits a marketing authorisation application in Europe for its sublingual house dust mite allergen immunotherapy tablet
Jan 13, 2020: New clinical trial for ALK’s house dust mite tablet paves the way for early registration in China
Jun 03, 2019: Targeted early treatment with ALKs ACARIZAX could improve allergic asthma treatment, allergy congress hears
May 31, 2019: Stallergenes Greer will be at 2019 EAACI Congress and present the results of its phase III House Dust Mites Tablet trial
Nov 20, 2018: Stallergenes Greer announces that the phase III trial for its sublingual allergy immunotherapy tablet STAGR320 to treat house dust mite-induced allergic rhinitis achieved its primary endpoint
May 29, 2018: Allergy Therapeutics - Positive new data with house-dust mite immunotherapy
Feb 21, 2018: New medicine for house dust mite allergic rhinitis and allergic asthma now available in France
Feb 16, 2018: Shionogi Got Approval of Partial Change Application in Dosage and Administration in Japan of Actair for Allergen Immunotherapy of Pediatric Allergic Rhinitis Caused by House Dust Mites
Feb 16, 2018: Torii Receives Approval for Additional Dosage and Administration for Pediatric Indication for MITICURE House Dust Mite Sublingual Tablets
Jan 11, 2018: New Treatment for House Dust Mite (HDM) - Induced Allergic Rhinitis Now Available in US
Nov 30, 2017: ALK secures pricing and reimbursement for ACARIZAX in France
Sep 26, 2017: Stallergenes Greer Advances Its House Dust Mite Allergy Pipeline With Acceptance Of Regulatory Submission And New Market Approval
Aug 21, 2017: ALK to accelerate launches of ODACTRA in the USA / ACARIZAX in Canada
Jul 27, 2017: Stallergenes Greer Announces Completion of Enrollment in Largest Phase III Study to Treat House Dust Mites Allergy
May 04, 2017: ALK's HDM SLIT-tablet, ACARIZAX, approved in Canada
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for House Dust Mite Allergy, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
House Dust Mite Allergy - Pipeline by Advagene Biopharma Co Ltd, 2021
House Dust Mite Allergy - Pipeline by ALK-Abello AS, 2021
House Dust Mite Allergy - Pipeline by Allergy Therapeutics Plc, 2021
House Dust Mite Allergy - Pipeline by Anergis SA, 2021
House Dust Mite Allergy - Pipeline by Astellas Pharma Inc, 2021
House Dust Mite Allergy - Pipeline by Biomay AG, 2021
House Dust Mite Allergy - Pipeline by Genetic Immunity Inc, 2021
House Dust Mite Allergy - Pipeline by Polyrizon Ltd, 2021
House Dust Mite Allergy - Pipeline by Roxall Medizin GmbH, 2021
House Dust Mite Allergy - Pipeline by Stallergenes Greer Ltd, 2021
House Dust Mite Allergy - Pipeline by Zhejiang I-Biological Technology Co Ltd, 2021
House Dust Mite Allergy - Dormant Projects, 2021
House Dust Mite Allergy - Discontinued Products, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development for House Dust Mite Allergy, 2021
Number of Products under Development by Companies, 2021
Number of Products by Stage and Targets, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021